The FDA’s Pressure-Packed Alzheimer’s Drug Decision

<p>The U.S. Food and Drug Administration faces a costly and consequential decision over whether to approve a controversial new Alzheimer’s drug.</p><p><br></p><p>Guest:</p><p><a href="https://www.jhsph.edu/faculty/directory/profile/2761/caleb-alexander" rel="noopener noreferrer" target="_blank">Caleb Alexander</a>, Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health</p><p><br></p><p>View the transcript for today's episode: <a href="https://tradeoffs.org/2021/06/03/the-fdas-pressure-packed-alzheimers-drug-decision" rel="noopener noreferrer" target="_blank">https://tradeoffs.org/2021/06/03/the-fdas-pressure-packed-alzheimers-drug-decision</a></p><p><br></p><p>Take our short listener survey, and you could win a $50 gift card! <a href="https://survey.sogosurvey.com/Survey1.aspx?k=RQsRRRXQRsQsPsPsP&amp;lang=0" rel="noopener noreferrer" target="_blank">bit.ly/TradeoffsSurvey</a></p><p><br></p><p>Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: <a href="https://mailchi.mp/63a60bee39a5/tradeoffsnewsletter" rel="noopener noreferrer" target="_blank">bit.ly/tradeoffsnewsletter</a></p><p><br></p><p>Support this type of journalism today, with a gift: <a href="https://tradeoffs.org/donate" rel="noopener noreferrer" target="_blank">https://tradeoffs.org/donate</a></p><p><br></p><p>Follow us on Twitter:&nbsp;<a href="https://twitter.com/tradeoffspod" rel="noopener noreferrer" target="_blank">https://twitter.com/tradeoffspod</a></p> &#10;&nbsp;<br /><hr><p style='color: grey; font - size: 0.75em; '>See <a style='color: grey; ' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.</p>